US3308020A
(en)
|
1961-09-22 |
1967-03-07 |
Merck & Co Inc |
Compositions and method for binding bile acids in vivo including hypocholesteremics
|
US3383281A
(en)
|
1961-09-22 |
1968-05-14 |
Merck & Co Inc |
Method for binding bile acids in vivo
|
GB1348642A
(en)
|
1970-10-15 |
1974-03-20 |
Howard A N |
Hypocholesterolaemic compositions
|
US3769399A
(en)
|
1971-03-05 |
1973-10-30 |
L Hagerman |
Intestinal bile acid binding process and compositions
|
US3974272A
(en)
|
1972-09-01 |
1976-08-10 |
Merck & Co., Inc. |
Palatable cholestyramine coacervate compositions
|
US4252790A
(en)
|
1974-10-23 |
1981-02-24 |
Interx Research Corporation |
Method for treating gastric ulcer-prone patients
|
GB1566609A
(en)
|
1977-03-10 |
1980-05-08 |
Reckitt & Colmann Prod Ltd |
Pharmaceutical compositions containing cholestyramine and alginic acid
|
IT1106718B
(it)
|
1978-12-21 |
1985-11-18 |
Alfa Farmaceutici Spa |
Composizioni a base di resine anioniche salificate farmacologicamente attive
|
NO170760C
(no)
|
1985-01-10 |
1992-12-02 |
Tanabe Seiyaku Co |
Analogifremgangsmaate for fremstilling av terapeutisk aktive nafthalenderivater
|
JPS6310746A
(ja)
|
1986-07-01 |
1988-01-18 |
Tanabe Seiyaku Co Ltd |
ナフタレン誘導体
|
US4895723A
(en)
|
1986-09-08 |
1990-01-23 |
Amer And Company |
Cholestyramine compositions and method for preparation thereof
|
US4814354A
(en)
|
1986-09-26 |
1989-03-21 |
Warner-Lambert Company |
Lipid regulating agents
|
US4874744A
(en)
|
1989-03-13 |
1989-10-17 |
University Of Cincinnati |
Method of using melanocyte stimulating hormone as dermatis treatment
|
DE3930696A1
(de)
|
1989-09-14 |
1991-03-28 |
Hoechst Ag |
Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
|
FI106800B
(fi)
|
1990-12-06 |
2001-04-12 |
Hoechst Ag |
Menetelmä uusien terapeuttisesti käyttökelpoisten dimeeristen sappihappojohdannaisten valmistamiseksi
|
KR100252428B1
(ko)
|
1991-10-17 |
2000-04-15 |
시오노 요시히코 |
리그난유사체,이의제조방법및이를함유한항지혈증제
|
AU653658B2
(en)
|
1991-12-20 |
1994-10-06 |
Hoechst Aktiengesellschaft |
Polymers and oligomers of bile acid derivatives, process for their preparation and their use as pharmaceuticals
|
GB9203347D0
(en)
|
1992-02-17 |
1992-04-01 |
Wellcome Found |
Hypolipidaemic compounds
|
EP0573848B1
(de)
|
1992-06-12 |
1997-12-03 |
Hoechst Aktiengesellschaft |
Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel
|
ZA941003B
(en)
|
1993-02-15 |
1995-08-14 |
Wellcome Found |
Hypolipidaemic compounds
|
IL108634A0
(en)
|
1993-02-15 |
1994-05-30 |
Wellcome Found |
Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
|
CN1046937C
(zh)
|
1993-04-16 |
1999-12-01 |
盐野义制药株式会社 |
木酚素系化合物的制备方法
|
DE4314583A1
(de)
|
1993-04-29 |
1994-11-03 |
Astra Chem Gmbh |
Colestyramin enthaltende Zusammensetzung und Verfahren zu deren Herstellung
|
TW289020B
(es)
|
1993-05-08 |
1996-10-21 |
Hoechst Sktiengesellschaft |
|
TW289021B
(es)
|
1993-05-08 |
1996-10-21 |
Hoechst Ag |
|
EP0624593A3
(de)
|
1993-05-08 |
1995-06-07 |
Hoechst Ag |
Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
|
ZA956647B
(en)
|
1994-08-10 |
1997-02-10 |
Wellcome Found |
Hypolipidaemic compounds.
|
US6262277B1
(en)
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
JP3304093B2
(ja)
|
1994-09-13 |
2002-07-22 |
モンサント カンパニー |
回腸の胆汁酸輸送及びタウロコール酸塩吸収の阻害活性を有する新規ベンゾチエピン類
|
US5994391A
(en)
|
1994-09-13 |
1999-11-30 |
G.D. Searle And Company |
Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
US6107494A
(en)
|
1994-09-13 |
2000-08-22 |
G.D. Searle And Company |
Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
GB9423172D0
(en)
|
1994-11-17 |
1995-01-04 |
Wellcom Foundation The Limited |
Hypolipidemic benzothiazepines
|
CN1110494C
(zh)
|
1996-03-11 |
2003-06-04 |
G·D·瑟尔公司 |
具有作为回肠胆汁酸转运和牛磺胆酸盐吸收抑制剂活性的新的苯并噻庚因
|
EP0929575A4
(en)
|
1996-08-23 |
2004-09-08 |
Human Genome Sciences Inc |
NEW HUMAN GROWTH FACTORS.
|
JPH1072371A
(ja)
|
1996-08-28 |
1998-03-17 |
Sankyo Co Ltd |
回腸型胆汁酸トランスポーター阻害剤
|
GB9704208D0
(en)
|
1997-02-28 |
1997-04-16 |
Glaxo Group Ltd |
Chemical compounds
|
WO1998040375A2
(en)
|
1997-03-11 |
1998-09-17 |
G.D. Searle & Co. |
COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS
|
DK0864582T3
(da)
|
1997-03-14 |
2003-09-29 |
Aventis Pharma Gmbh |
Hypolidemiske 1,4-benzothiazepin-1,1-dioxider
|
ATE268758T1
(de)
|
1997-04-04 |
2004-06-15 |
Aventis Pharma Gmbh |
Hypolipidämische propanolaminderivate
|
DE19845402B4
(de)
|
1998-10-02 |
2005-04-07 |
Aventis Pharma Deutschland Gmbh |
Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
AU7552198A
(en)
|
1997-06-11 |
1998-12-30 |
Sankyo Company Limited |
Benzylamine derivatives
|
US6066336A
(en)
|
1997-09-29 |
2000-05-23 |
Bristol-Myers Squibb Company |
Cholesterol-lowering tablets
|
BR9814300A
(pt)
|
1997-12-19 |
2002-02-05 |
Searle & Co |
Método de preparação de óxidos de tetraidrobenzotiepina enanciomericamente enriquecidos
|
GB9800428D0
(en)
|
1998-01-10 |
1998-03-04 |
Glaxo Group Ltd |
Chemical compounds
|
DE19825804C2
(de)
|
1998-06-10 |
2000-08-24 |
Aventis Pharma Gmbh |
1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
|
DE19831210A1
(de)
|
1998-07-03 |
2000-01-05 |
Wita Gmbh Wittmann Inst Of Tec |
Verfahren und Vorrichtung zur zwei-dimensionalen Trennung von Biomolekülen
|
DE19845403B4
(de)
|
1998-10-02 |
2005-02-10 |
Aventis Pharma Deutschland Gmbh |
Mit Gallensäuren verknüpfte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
DE19845406C2
(de)
|
1998-10-02 |
2001-10-18 |
Aventis Pharma Gmbh |
Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
AU1684400A
(en)
|
1998-12-11 |
2000-07-03 |
Sankyo Company Limited |
Substituted benzylamines
|
HUP0201972A3
(en)
|
1998-12-23 |
2005-06-28 |
G D Searle Llc Chicago |
Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
|
BR9916565A
(pt)
|
1998-12-23 |
2002-01-29 |
Searle Llc |
Combinações de inibidores do transporte ácido da bile ileal e derivados do ácido fìbrico para indicações cardiovasculares
|
BR9916564A
(pt)
|
1998-12-23 |
2002-01-29 |
Searle Llc |
Combinações para indicações cardiovasculares
|
ES2189529T3
(es)
|
1998-12-23 |
2003-07-01 |
Searle Llc |
Combinaciones de inhiidores para el transporte de acidos biliares en el ileon y agentes complejantes para indicaciones cardiovasculares.
|
CA2362147A1
(en)
|
1999-02-12 |
2000-08-17 |
Steve A. Kolodziej |
1,2-benzothiazepines for the treatment of hyperlipidemic diseases
|
DE19916108C1
(de)
|
1999-04-09 |
2001-01-11 |
Aventis Pharma Gmbh |
Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
|
TR200002099A3
(tr)
|
1999-07-22 |
2001-06-21 |
Sankyo Company Limited |
Siklobüten türevleri, bunlarin hazirlanmasi ve terapötik kullanimlari
|
EP1212619B1
(en)
|
1999-09-14 |
2007-05-23 |
Xenoport, Inc. |
Substrates and screening methods for transport proteins
|
WO2001034570A1
(fr)
|
1999-11-08 |
2001-05-17 |
Sankyo Company, Limited |
Derives heterocycliques azotes
|
SE0000772D0
(sv)
|
2000-03-08 |
2000-03-08 |
Astrazeneca Ab |
Chemical compounds
|
AU2001247331A1
(en)
|
2000-03-10 |
2001-09-24 |
Pharmacia Corporation |
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
|
AU2001240115A1
(en)
|
2000-03-10 |
2001-09-24 |
Pharmacia Corporation |
Method for the preparation of tetrahydrobenzothiepines
|
US20020183307A1
(en)
|
2000-07-26 |
2002-12-05 |
Tremont Samuel J. |
Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
|
SK7822003A3
(en)
|
2000-12-21 |
2003-12-02 |
Aventis Pharma Gmbh |
Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
|
EG26979A
(en)
|
2000-12-21 |
2015-03-01 |
Astrazeneca Ab |
Chemical compounds
|
NZ542090A
(en)
|
2001-01-26 |
2006-09-29 |
Schering Corp |
Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
|
DE60220522T2
(de)
|
2001-07-19 |
2007-09-27 |
Pharmacia Corp. |
Kombination von einem aldosterone rezeptor antagonisten und einem hmg coa reduktase hemmer
|
HUP0401318A3
(en)
|
2001-08-22 |
2008-03-28 |
Sanofi Aventis Deutschland |
Combined preparations containing 2,3,4,5-tetrahydro-benzo[b]thiepine-1,1-dioxide derivatives and other active substances, and the use thereof
|
GB0121337D0
(en)
|
2001-09-04 |
2001-10-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0121622D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
GB0121621D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
IL160691A0
(en)
|
2001-09-08 |
2004-08-31 |
Astrazeneca Ab |
Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment of hyperlipidaemia
|
DE60216300T2
(de)
|
2001-09-21 |
2007-06-28 |
Schering Corp. |
Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
|
WO2003040127A1
(en)
|
2001-11-02 |
2003-05-15 |
G.D. Searle Llc |
Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake
|
CA2471639A1
(en)
|
2002-01-17 |
2003-07-31 |
Pharmacia Corporation |
Novel alkyl/aryl hydroxy or keto thiepines.
|
US20040014806A1
(en)
|
2002-03-08 |
2004-01-22 |
Pharmacia Corporation |
Methods and compositions for lowering levels of blood lipids
|
GB0209467D0
(en)
|
2002-04-25 |
2002-06-05 |
Astrazeneca Ab |
Chemical compounds
|
GB0215579D0
(en)
|
2002-07-05 |
2002-08-14 |
Astrazeneca Ab |
Chemical compounds
|
AU2003291719A1
(en)
|
2002-11-06 |
2004-06-03 |
Schering Corporation |
Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
|
US20050031651A1
(en)
|
2002-12-24 |
2005-02-10 |
Francine Gervais |
Therapeutic formulations for the treatment of beta-amyloid related diseases
|
DE602004018617D1
(de)
|
2003-03-07 |
2009-02-05 |
Schering Corp |
Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
|
CN1756755A
(zh)
|
2003-03-07 |
2006-04-05 |
先灵公司 |
取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
|
GB0307918D0
(en)
|
2003-04-05 |
2003-05-14 |
Astrazeneca Ab |
Therapeutic use
|
WO2005046797A2
(en)
|
2003-11-05 |
2005-05-26 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
EP1564554A1
(en)
|
2004-02-12 |
2005-08-17 |
Pepscan Systems B.V. |
Method for the detection of early B cell populations in vaccine development
|
DE102004016845A1
(de)
|
2004-04-07 |
2005-10-27 |
Bayer Healthcare Ag |
Phenylthioessigsäure-Derivate und ihre Verwendung
|
WO2006017257A2
(en)
|
2004-07-12 |
2006-02-16 |
Phenomix Corporation |
Azetidinone derivatives
|
DE102004046623A1
(de)
|
2004-09-25 |
2006-03-30 |
Bayer Healthcare Ag |
Neue Pyrimidin-Derivate und ihre Verwendung
|
WO2006039334A1
(en)
|
2004-09-29 |
2006-04-13 |
Schering Corporation |
Combinations of substituted azetidonones and cb1 antagonists
|
WO2006041150A1
(ja)
|
2004-10-15 |
2006-04-20 |
Mitsubishi Pharma Corporation |
糖尿病の予防および/または治療薬
|
AU2005311930B9
(en)
|
2004-12-03 |
2009-09-10 |
Merck Sharp & Dohme Corp. |
Substituted piperazines as CB1 antagonists
|
DE102005027150A1
(de)
|
2005-03-12 |
2006-09-28 |
Bayer Healthcare Ag |
Pyrimidincarbonsäure-Derivate und ihre Verwendung
|
US8207133B1
(en)
|
2005-04-04 |
2012-06-26 |
Julius-Maximilians-Universitat Wurzburg |
Peptides that down regulate the activity of plasma membrane transporters including sodium-D-glucose cotransporter SGLT1
|
EP1896049B1
(en)
|
2005-04-04 |
2017-11-29 |
Julius-Maximilians-Universität Würzburg |
Tripeptides that down regulate the activity of plasma membrane transporters including sodium-d-glucose cotransporter sglt1
|
JP2008539255A
(ja)
|
2005-04-26 |
2008-11-13 |
マイクロビア インコーポレーテッド |
高コレステロール血症のための4−ビアリーリル−1−フェニルアゼチジン−2−オングルクロニド誘導体
|
DE102005020229A1
(de)
|
2005-04-30 |
2006-11-09 |
Bayer Healthcare Ag |
Verwendung von Indolin-Phenylsulfonamid-Derivaten
|
EP1877373A2
(en)
|
2005-05-05 |
2008-01-16 |
Microbia, Inc. |
Biphenylazetidinone cholesterol absorption inhibitors
|
WO2006122186A2
(en)
|
2005-05-10 |
2006-11-16 |
Microbia, Inc. |
1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
|
EP1885694A2
(en)
|
2005-05-13 |
2008-02-13 |
Microbia, Inc. |
4-biarylyl-1-phenylazetidin-2-ones
|
EP1931665A1
(en)
|
2005-09-20 |
2008-06-18 |
Schering Corporation |
1-[[1-[(2-amin0-6-methyl-4-pyridinyl)methyl]-4-flu0r0-4-piperidinyl,]carbonyl]-4-[2-(2-pyridinyl)-3h-imidaz0[4, 5-b]pyridin-3-yl]piperidine useful as histamine h3 antagonist
|
WO2007050628A2
(en)
|
2005-10-24 |
2007-05-03 |
Andrew Young |
Biliary/pancreatic shunt device and method for treatment of metabolic and other diseases
|
EP1962838B1
(en)
|
2005-12-19 |
2011-09-28 |
GlaxoSmithKline LLC |
Farnesoid x receptor agonists
|
MX2008008340A
(es)
|
2005-12-21 |
2008-09-03 |
Schering Corp |
Tratamiento de enfermedad de higado graso no alcoholica usando agentes reductores de colesterol y/o antagonista/agonista inverso de receptor de histamina 3.
|
EP1987000A2
(en)
|
2006-01-13 |
2008-11-05 |
Schering Corporation |
Diaryl piperidines as cb1 modulators
|
PE20071320A1
(es)
|
2006-01-18 |
2007-12-29 |
Schering Corp |
Moduladores de receptores cannabinoides
|
DE102006009813A1
(de)
|
2006-03-01 |
2007-09-06 |
Bayer Healthcare Ag |
Verwendung von A2b/A1 Rezeptor Agonisten zur Modulation der Lipidspiegel
|
US20070254952A1
(en)
|
2006-04-21 |
2007-11-01 |
Yuguang Wang |
Cannabinoid receptor modulators
|
DE102006024024A1
(de)
|
2006-05-23 |
2007-11-29 |
Bayer Healthcare Aktiengesellschaft |
Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
|
DE102006026585A1
(de)
|
2006-06-07 |
2007-12-13 |
Bayer Healthcare Aktiengesellschaft |
Substituierte 4-Aryl-1,4-dihydro-1,6-naphthyridine und ihre Verwendung
|
DE102006026583A1
(de)
|
2006-06-07 |
2007-12-13 |
Bayer Healthcare Aktiengesellschaft |
Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung
|
DE102006042143A1
(de)
|
2006-09-08 |
2008-03-27 |
Bayer Healthcare Aktiengesellschaft |
Neue substituierte Bipyridin-Derivate und ihre Verwendung
|
DE102006043520A1
(de)
|
2006-09-12 |
2008-03-27 |
Bayer Healthcare Ag |
2-Phenoxynikotinsäure-Derivate und ihre Verwendung
|
DE102006043519A1
(de)
|
2006-09-12 |
2008-03-27 |
Bayer Healthcare Ag |
4-Phenoxynikotinsäure-Derivate und ihre Verwendung
|
JP2010503673A
(ja)
|
2006-09-15 |
2010-02-04 |
シェーリング コーポレイション |
疼痛および脂質代謝障害を処置する際に有用なアゼチジン誘導体およびアゼチドン誘導体
|
WO2008033464A2
(en)
|
2006-09-15 |
2008-03-20 |
Schering Corporation |
Azetidinone derivatives for the treatment of disorders of the lipid metabolism
|
CN101528746A
(zh)
|
2006-09-15 |
2009-09-09 |
先灵公司 |
治疗脂质代谢障碍、疼痛、糖尿病和其它障碍的螺环氮杂环丁酮衍生物
|
WO2008034087A2
(en)
|
2006-09-15 |
2008-03-20 |
Xenoport, Inc. |
Treating schizophrenia with combinations of levodopa and an antipsychotic agent
|
EP2091534A1
(en)
|
2006-09-15 |
2009-08-26 |
Schering Corporation |
Azetidinone derivatives and methods of use thereof
|
US7638526B2
(en)
|
2006-09-15 |
2009-12-29 |
Schering Corporation |
Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism
|
CA2663504A1
(en)
|
2006-09-15 |
2008-03-20 |
Schering Corporation |
Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
|
WO2008033460A2
(en)
|
2006-09-15 |
2008-03-20 |
Schering Corporation |
Treating pain, diabetes, and lipid metabolism disorders
|
DE102006044696A1
(de)
|
2006-09-22 |
2008-03-27 |
Bayer Healthcare Ag |
3-Cyano-5-thiazaheteroaryl-dihydropyridine und ihre Verwendung
|
WO2008039829A2
(en)
|
2006-09-26 |
2008-04-03 |
Ironwood Pharmaceuticals, Inc. |
Diphenylheterocycle cholesterol absorption inhibitors
|
CL2007003035A1
(es)
|
2006-10-24 |
2008-05-16 |
Smithkline Beechman Corp |
Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
|
US20080161400A1
(en)
|
2006-10-26 |
2008-07-03 |
Xenoport, Inc. |
Use of forms of propofol for treating diseases associated with oxidative stress
|
DE102006056740A1
(de)
|
2006-12-01 |
2008-06-05 |
Bayer Healthcare Ag |
Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
|
DE102006056739A1
(de)
|
2006-12-01 |
2008-06-05 |
Bayer Healthcare Ag |
Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
|
CA2674683A1
(en)
|
2007-01-16 |
2008-07-24 |
The Burnham Institute For Medical Research |
Compositions and methods for treatment of colorectal cancer
|
DE102007009494A1
(de)
|
2007-02-27 |
2008-08-28 |
Bayer Healthcare Ag |
Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
|
WO2008124505A2
(en)
|
2007-04-05 |
2008-10-16 |
Ironwood Pharmaceuticals,Inc. |
Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
|
WO2008130616A2
(en)
|
2007-04-19 |
2008-10-30 |
Schering Corporation |
Diaryl morpholines as cb1 modulators
|
ES2552657T3
(es)
*
|
2010-05-26 |
2015-12-01 |
Satiogen Pharmaceuticals, Inc. |
Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
|
CA2842707A1
(en)
*
|
2011-08-04 |
2013-02-07 |
Lumena Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of pancreatitis
|